# A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

> **NCT02791516** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 67 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02791516
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2018-02-12
- **Final completion:** 2018-12-21
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791516, "A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02791516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*